CN105188705A - 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法 - Google Patents

包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法 Download PDF

Info

Publication number
CN105188705A
CN105188705A CN201480025177.5A CN201480025177A CN105188705A CN 105188705 A CN105188705 A CN 105188705A CN 201480025177 A CN201480025177 A CN 201480025177A CN 105188705 A CN105188705 A CN 105188705A
Authority
CN
China
Prior art keywords
alkyl
substituted
methyl
aromatic ring
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480025177.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·格雷姆贝卡
T·切尔皮基
德米特里·博尔金
J·赫斯
D·孙
X·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CN105188705A publication Critical patent/CN105188705A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480025177.5A 2013-03-13 2014-03-10 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法 Pending CN105188705A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
US61/780,099 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CN105188705A true CN105188705A (zh) 2015-12-23

Family

ID=51529943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480025177.5A Pending CN105188705A (zh) 2013-03-13 2014-03-10 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法

Country Status (11)

Country Link
US (4) US9505781B2 (https=)
EP (1) EP2968342B1 (https=)
JP (2) JP2016512514A (https=)
KR (1) KR20150130389A (https=)
CN (1) CN105188705A (https=)
AU (1) AU2014249233A1 (https=)
BR (1) BR112015022602A2 (https=)
CA (1) CA2904612A1 (https=)
IL (1) IL241193A0 (https=)
MX (1) MX2015011576A (https=)
WO (1) WO2014164543A1 (https=)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152784A (zh) * 2016-03-16 2019-01-04 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987A (zh) * 2016-03-16 2019-04-16 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109689663A (zh) * 2016-09-14 2019-04-26 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN109715634A (zh) * 2016-09-14 2019-05-03 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
CN109743875A (zh) * 2016-06-10 2019-05-10 生命医药公司 Menin-mll相互作用的抑制剂
CN110204552A (zh) * 2018-02-28 2019-09-06 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CN110248946A (zh) * 2016-12-15 2019-09-17 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
CN110691779A (zh) * 2017-03-24 2020-01-14 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
CN113677341A (zh) * 2019-02-01 2021-11-19 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN114929705A (zh) * 2020-05-28 2022-08-19 诺华公司 Mll1抑制剂及抗癌剂
CN115003677A (zh) * 2019-11-29 2022-09-02 大鹏药品工业株式会社 对kras g12d突变具有抑制活性的化合物
CN116199633A (zh) * 2022-12-27 2023-06-02 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102215272B1 (ko) * 2012-09-28 2021-02-15 이그니타, 인코포레이티드 비정형 단백질 키나제 c의 아자퀴나졸린 억제제
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
TWI703150B (zh) * 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) * 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10869868B2 (en) * 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
MX2019011412A (es) 2017-03-31 2020-02-07 Univ Michigan Regents Piperidinas como inhibidores de menina covalentes.
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) * 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP7307729B2 (ja) * 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
ES2991898T3 (es) * 2018-08-08 2024-12-05 Sumitomo Pharma Co Ltd Derivado de piperidina con puente ópticamente activo
CA3112340A1 (en) 2018-10-03 2020-04-09 The Regents Of The University Of Michigan Small molecule menin inhibitors
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
AU2019395201A1 (en) * 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
EP4132932A4 (en) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
EP4232020A4 (en) * 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CA3215379A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
US20240417405A1 (en) 2021-05-08 2024-12-19 Janssen Pharmaceutica Nv Substituted Spiro Derivatives
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
JP2024521902A (ja) 2021-06-03 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
WO2022262796A1 (en) 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
CA3244647A1 (en) * 2021-12-31 2025-06-13 Hitgen Inc. MENINO-MLL INHIBITOR AND ITS USE
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153556A1 (en) * 2001-09-06 2003-08-14 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20110065690A1 (en) * 2009-09-04 2011-03-17 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
US8207174B2 (en) * 2007-01-22 2012-06-26 4Sc Ag Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
CN102186479A (zh) * 2008-09-10 2011-09-14 凯利普西斯公司 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
EP2459533A4 (en) * 2009-07-30 2013-01-16 Univ Singapore SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153556A1 (en) * 2001-09-06 2003-08-14 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US8207174B2 (en) * 2007-01-22 2012-06-26 4Sc Ag Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments
US20110065690A1 (en) * 2009-09-04 2011-03-17 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152784B (zh) * 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987A (zh) * 2016-03-16 2019-04-16 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109152784A (zh) * 2016-03-16 2019-01-04 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987B (zh) * 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN114539284A (zh) * 2016-03-16 2022-05-27 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109743875A (zh) * 2016-06-10 2019-05-10 生命医药公司 Menin-mll相互作用的抑制剂
CN109743875B (zh) * 2016-06-10 2022-04-29 生命医药有限责任公司 Menin-mll相互作用的抑制剂
CN109689663B (zh) * 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN109715634B (zh) * 2016-09-14 2022-09-27 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109689663A (zh) * 2016-09-14 2019-04-26 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN109715634A (zh) * 2016-09-14 2019-05-03 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US11220517B2 (en) 2016-09-14 2022-01-11 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN110248946A (zh) * 2016-12-15 2019-09-17 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
CN110248946B (zh) * 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
CN110691779A (zh) * 2017-03-24 2020-01-14 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CN110691779B (zh) * 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CN110204552A (zh) * 2018-02-28 2019-09-06 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CN113677341A (zh) * 2019-02-01 2021-11-19 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
CN115003677A (zh) * 2019-11-29 2022-09-02 大鹏药品工业株式会社 对kras g12d突变具有抑制活性的化合物
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
CN114929705A (zh) * 2020-05-28 2022-08-19 诺华公司 Mll1抑制剂及抗癌剂
CN114929705B (zh) * 2020-05-28 2024-09-13 诺华公司 Mll1抑制剂及抗癌剂
US12371434B2 (en) 2020-05-28 2025-07-29 China Novartis Institutes For Biomedical Research Co., Ltd. MLL1 inhibitors and anti-cancer agents
CN116199633A (zh) * 2022-12-27 2023-06-02 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法

Also Published As

Publication number Publication date
JP6670885B2 (ja) 2020-03-25
US20160137665A1 (en) 2016-05-19
US20170253611A1 (en) 2017-09-07
WO2014164543A1 (en) 2014-10-09
MX2015011576A (es) 2016-05-16
US9505781B2 (en) 2016-11-29
IL241193A0 (en) 2015-11-30
CA2904612A1 (en) 2014-10-09
US9216993B2 (en) 2015-12-22
AU2014249233A1 (en) 2015-09-24
US10160769B2 (en) 2018-12-25
US20140275070A1 (en) 2014-09-18
BR112015022602A2 (pt) 2017-07-18
EP2968342B1 (en) 2018-10-03
EP2968342A4 (en) 2016-07-27
US20160046647A1 (en) 2016-02-18
US9505782B2 (en) 2016-11-29
JP2016512514A (ja) 2016-04-28
JP2018115214A (ja) 2018-07-26
KR20150130389A (ko) 2015-11-23
EP2968342A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
CN105188705A (zh) 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法
TWI863945B (zh) 2-側氧基喹唑啉衍生物作為甲硫胺酸腺苷基轉移酶２ａ抑制劑
ES3036496T3 (en) Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
ES2615238T3 (es) Derivados de tetrahidroquinolinas como inhibidores de bromodominio
KR101749192B1 (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
CN103974948B (zh) 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑
CN102816162B (zh) 嘧啶并嘧啶酮类化合物及其药用组合物和应用
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
CN103958502B (zh) 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
US11718601B2 (en) Pyridinyl substituted oxoisoindoline compounds
TW202322796A (zh) 靶向p53突變體的化合物
WO2024255782A1 (zh) 双环衍生物parp抑制剂及其用途
BR112016012844B1 (pt) Composto e composições farmacêuticas
KR20230112605A (ko) 키나아제 억제제 및 그의 용도
WO2022148196A1 (zh) 多激酶抑制剂及其用途
JP2005526764A (ja) ピリミジン化合物
JP2024540264A (ja) ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用
CN112543757A (zh) 对结核菌具有抗菌活性的缩合氮杂杂芳基化合物
WO2023011446A1 (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CN117730080A (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
TW202432545A (zh) 可活化sting之雜環化合物
WO2025252241A1 (zh) 一种大环衍生物及其用途
CN115515958A (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CN118772113A (zh) 作为DNA聚合酶Theta抑制剂的含氮杂环化合物
WO2021168521A1 (en) Inhibitors of necroptosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151223